Loading
A phase 1/2 trial of Daraxonrasib, Elironrasib, Zoldonrasib in non-small-cell lung cancer and small-cell lung cancer, run by Revolution Medicines, Inc., now recruiting.
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors is a phase 1/2 interventional study registered as NCT07397338 by Revolution Medicines, Inc., with 370 participants planned, started 2026-01-30 and due to reach its primary completion in 2029-05. Interventions recorded: Daraxonrasib, Elironrasib, Zoldonrasib, Ivonescimab, Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only). Conditions listed: Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Elironrasib, Revolution Medicines, Daraxonrasib, Cisplatin.
Shares Zoldonrasib, Revolution Medicines, Cisplatin, Carboplatin.
Shares Elironrasib, Revolution Medicines, Daraxonrasib, Small-cell lung cancer.
Shares Ivonescimab, Bispecific antibodies, Carboplatin, Small-cell lung cancer.
Shares Zoldonrasib, Revolution Medicines, Daraxonrasib, Colorectal cancer.
Shares Zoldonrasib, Revolution Medicines, Daraxonrasib, Colorectal cancer.
Shares Ivonescimab, Bispecific antibodies, Carboplatin, Small-cell lung cancer.
Shares Revolution Medicines, Daraxonrasib, Small-cell lung cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/